Listed

Monte Rosa Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2026

Filed with the SEC on May 7, 2026 and accepted by EDGAR at May 7, 2026, 11:30 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-01-01 to 2026-03-31$4.2mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Research and development3 months2026-01-01 to 2026-03-31$44.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2026-01-01 to 2026-03-31−$50.0mus-gaap:OperatingIncomeLoss
Income tax3 months2026-01-01 to 2026-03-31$52.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-01-01 to 2026-03-31−$44.5mus-gaap:NetIncomeLoss
Diluted shares (weighted)3 months2026-01-01 to 2026-03-3199,883,878 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2026-01-01 to 2026-03-31−$37.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2026-01-01 to 2026-03-31$1.9mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2026-01-01 to 2026-03-31$0us-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2026-03-31$159.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-03-31$677.5mus-gaap:AssetsCurrent
Total assetsAt period end2026-03-31$736.4mus-gaap:Assets
Current liabilitiesAt period end2026-03-31$71.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-03-31$214.5mus-gaap:Liabilities
Shareholders' equityAt period end2026-03-31$521.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-26-210358. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.